Skip to search formSkip to main contentSkip to account menu

AZD 0530

Known as: AZD-0530, AZD0530 
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. AZD0530 is a dual-specific inhibitor of Src… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

saracatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The SRC kinase inhibitor saracatinib limits the development of osteolytic bone disease in multiple myeloma
Despite recent advances in therapy, multiple myeloma (MM) remains an incurable disease. MM-associated osteolytic bone disease… 
2011
2011
Abstract 1783: Distinctive effects of the Src-inhibitor, saracatinib (AZD0530), on T-cell activation and differentiation: A basic study to combine Src-inhibitor and vaccine based-cancer immunotherapy
Targeted inhibitors have become attractive as novel therapies against cancer. Inhibition of Src-family kinases (SFK) is… 
2010
2010
Abstract P2-19-03: Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC)
Background: p27 is a negative regulator of cell cycle that is frequently decreased in primary human breast cancer (BC) due to… 
2010
2010
Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
8562 Background: The Src family kinases Fyn, Yes, and Src have variably been shown to be expressed and functionally active in… 
2010
2010
A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium.
e14544 Background: AZD0530is an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting c-SRC, c- Yes, Lck and… 
2009
2009
Cancer: A new therapeutic target for advanced thyroid cancer
schweppe and colleagues describe anti­ tumor effects of a novel, oral src inhibitor in papillary and anaplastic thyroid cancers… 
2008
2008
UIJ - Targeted therapy of bone lesions in prostate cancer using the specific Src kinase inhibitor AZD0530
2007
2007
Clinical Development of Src Family Kinase Inhibitors in Malignant Melanoma
Currently available systemic therapies for malignant melanoma are unsatisfactory and there is an urgent need for effective and… 
2007
2007
Combination of mek inhibitors and src kinase inhibitors azd0530 used in the treatment of cancer
The present invention includes a MEK inhibitor and Src kinase inhibitor AZD0530, relates to the combination used in the treatment… 
2006
2006
Combination therapy using AZD0530 and tamoxifen prevents antihormone resistance in breast cancer cells